Allogeneic_bone_marrow_transplantation_as_therapy_for_primary_induction_failure_for_patients_with_acute_leukemia._The_survival_of_patients_with_acute_leukemia_who_do_not_achieve_a_remission_with_primary_therapy_is_very_poor._High-dose_chemoradiotherapy_followed_by_allogeneic_bone_marrow_transplantation_(BMT)_has_been_shown_to_be_effective_therapy_for_patients_with_acute_and_chronic_leukemia._Therefore,_we_determined_the_long-term_disease-free_survival_of_patients_who_did_not_achieve_a_remission_and_were_then_treated_with_high-dose_therapy_and_bone_marrow_allografting_from_matched_sibling_donors._Twenty-one_patients_(median_age,_28_years)_who_did_not_achieve_a_remission_with_induction_chemotherapy_were_subsequently_treated_with_allogeneic_BMT._After_BMT,_90%_achieved_a_complete_remission._Six_died_of_complications_of_the_therapy,_and_six_patients_relapsed_between_27_and_448_days_after_BMT._Nine_patients_(43%;_median_age,_25_years)_are_alive_between_556_and_4,174_days_after_BMT._The_cumulative_probability_of_disease-free_survival_at_10_years_is_43%._This_study_suggests_that_allogeneic_BMT_can_be_an_effective_therapy_to_achieve_long-term_control_of_acute_leukemia,_even_in_those_patients_who_do_not_achieve_a_remission_with_primary_therapy.